Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

 

Rating

4.7 Star Rating for report Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016
4.7 / 5 stars rating
Pages: 294
Price: $2000.00

Some of our Clients

Some Research and Expert Clients

Abstract

 
Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.  

Description

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape.

Plaque psoriasis is a chronic, relapsing, inflammatory skin disorder. The frequency and intensity of psoriasis is affected by environmental factors such as smoking, sun exposure, alcoholism, and HIV infection. The symptoms of psoriasis include red patchy skin covered with silver scales, small scaling spots; dry cracked skin that may bleed; burning, itching, soreness, thickened, pitted or ridged nails; joint swelling and stiffening, and dandruff-like scaling over the scalp. Psoriasis is primarily diagnosed through an examination of the skin by dermatologist, as there are no blood tests or laboratory tests for a diagnosis of psoriasis.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8865IDBRheumatoid Arthritis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8834IDBGranulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeli...Dec 2016
Report... 05IB-GMDHC8821IDBSicca Syndrome (Sjogren) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8820IDBHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Defi...Dec 2016
Report... 05IB-GMDHC8720IDBAnaphylaxis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8637IDBSystemic Lupus Erythematosus - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8641IDBLung Transplant Rejection - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8650IDBPemphigus Vulgaris - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8594IDBPeanut Allergy - Pipeline Review, H2 2016Oct 2016
Report... 05IB-GMDHC8582IDBHematopoietic Stem Cell Transplantation - Pipeline Review, H2 20...Oct 2016

Report Source Information

Supplied by: Research and Experts 
Date Published: 2016-10-19 

Report: Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

 

Contents

Table of Contents
Table of Contents 2
Introduction 6
Plaque Psoriasis (Psoriasis Vulgaris) Overview 7
Therapeutics Development 8
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics under Development by Companies 9
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Products Glance 14
Plaque Psoriasis (Psoriasis Vulgaris) - Products under Development by Companies 18
Plaque Psoriasis (Psoriasis Vulgaris) - Companies Involved in Therapeutics Development 24
Plaque Psoriasis (Psoriasis Vulgaris) - Therapeutics Assessment 79
Drug Profiles 93
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects 261
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products 269
Plaque Psoriasis (Psoriasis Vulgaris) - Product Development Milestones 271
Appendix 283
 

List of Tables

List of Tables
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18
Number of Products under Development by Companies, H2 2016 20
Number of Products under Development by Companies, H2 2016 (Contd..1) 21
Number of Products under Development by Companies, H2 2016 (Contd..2) 22
Number of Products under Development by Companies, H2 2016 (Contd..3) 23
Comparative Analysis by Late Stage Development, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 25
Comparative Analysis by Early Stage Development, H2 2016 26
Comparative Analysis by Unknown Stage Development, H2 2016 27
Products under Development by Companies, H2 2016 28
Products under Development by Companies, H2 2016 (Contd..1) 29
Products under Development by Companies, H2 2016 (Contd..2) 30
Products under Development by Companies, H2 2016 (Contd..3) 31
Products under Development by Companies, H2 2016 (Contd..4) 32
Products under Development by Companies, H2 2016 (Contd..5) 33
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbbVie Inc, H2 2016 34
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AbGenomics International, Inc., H2 2016 35
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Almirall, S.A., H2 2016 36
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Alteogen Inc., H2 2016 37
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Amgen Inc., H2 2016 38
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by AstraZeneca Plc, H2 2016 39
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Avexxin AS, H2 2016 40
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by BIOCAD, H2 2016 41
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Biocon Limited, H2 2016 42
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bionovis SA, H2 2016 43
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 44
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Bristol-Myers Squibb Company, H2 2016 45
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by CalciMedica, Inc., H2 2016 46
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Can-Fite BioPharma Ltd., H2 2016 47
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cell Medica Limited, H2 2016 48
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Cellceutix Corporation, H2 2016 49
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Coherus BioSciences, Inc., H2 2016 50
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Eli Lilly and Company, H2 2016 51
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016 52
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Exicure, Inc., H2 2016 53
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Forward Pharma A/S, H2 2016 54
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Genor BioPharma Co Ltd, H2 2016 55
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by GlaxoSmithKline Plc, H2 2016 56
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 57
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Johnson & Johnson, H2 2016 58
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kadmon Corporation, LLC, H2 2016 59
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016 60
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by KPI Therapeutics, Inc., H2 2016 61
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by LEO Pharma A/S, H2 2016 62
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lipidor AB, H2 2016 63
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lupin Limited, H2 2016 64
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Lycera Corp., H2 2016 65
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Maruho Co., Ltd., H2 2016 66
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by MetrioPharm AG, H2 2016 67
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 68
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016 69
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Mycenax Biotech Inc., H2 2016 70
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by NeuClone Pty Ltd, H2 2016 71
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Novartis AG, H2 2016 72
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Oncobiologics, Inc., H2 2016 73
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Pfizer Inc., H2 2016 74
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Promius Pharma, LLC, H2 2016 75
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016 76
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016 77
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sandoz International GmbH, H2 2016 78
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Shanghai Celgen Bio-Pharmaceutical Co., Ltd., H2 2016 79
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 80
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 81
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 82
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by TheraMAB LLC, H2 2016 83
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Therapeutic Proteins International, LLC, H2 2016 84
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by UCB S.A., H2 2016 85
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016 86
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by XBiotech Inc, H2 2016 87
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline by Ziarco Pharma Ltd, H2 2016 88
Assessment by Monotherapy Products, H2 2016 89
Assessment by Combination Products, H2 2016 90
Number of Products by Stage and Target, H2 2016 92
Number of Products by Stage and Mechanism of Action, H2 2016 96
Number of Products by Stage and Route of Administration, H2 2016 100
Number of Products by Stage and Molecule Type, H2 2016 102
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects, H2 2016 271
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..1), H2 2016 272
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..2), H2 2016 273
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..3), H2 2016 274
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..4), H2 2016 275
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..5), H2 2016 276
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..6), H2 2016 277
Plaque Psoriasis (Psoriasis Vulgaris) - Dormant Projects (Contd..7), H2 2016 278
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products, H2 2016 279
Plaque Psoriasis (Psoriasis Vulgaris) - Discontinued Products (Contd..1), H2 2016 280
 

List of Figures

List of Figures
Number of Products under Development for Plaque Psoriasis (Psoriasis Vulgaris), H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Comparative Analysis by Late Stage Development, H2 2016 24
Comparative Analysis by Clinical Stage Development, H2 2016 25
Comparative Analysis by Early Stage Products, H2 2016 26
Assessment by Monotherapy Products, H2 2016 89
Assessment by Combination Products, H2 2016 90
Number of Products by Top 10 Targets, H2 2016 91
Number of Products by Stage and Top 10 Targets, H2 2016 91
Number of Products by Top 10 Mechanism of Actions, H2 2016 95
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 95
Number of Products by Routes of Administration, H2 2016 99
Number of Products by Stage and Routes of Administration, H2 2016 99
Number of Products by Molecule Types, H2 2016 101
Number of Products by Stage and Molecule Types, H2 2016 101
 

Scope


- The pipeline guide provides a snapshot of the global therapeutic landscape of Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology)

 

Highlights

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 20, 26, 13, 2, 11, 8 and 1 respectively for Plaque Psoriasis (Psoriasis Vulgaris).

Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Classification

Language Code: EN 
Region: Global 
Report Type: Market Report 
Industry: Life Sciences 
Sector: Immunology 
Pages: 294 

Companies Featured

AbbVie Inc AbGenomics International, Inc. Almirall, S.A. Alteogen Inc. Amgen Inc. AstraZeneca Plc Avexxin AS BIOCAD Biocon Limited Bionovis SA Boehringer Ingelheim GmbH Bristol-Myers Squibb Company CalciMedica, Inc. Can-Fite BioPharma Ltd. Cell Medica Limited Cellceutix Corporation Coherus BioSciences, Inc. Eli Lilly and Company Epirus Biopharmaceuticals, Inc. Exicure, Inc. Forward Pharma A/S Genor BioPharma Co Ltd GlaxoSmithKline Plc Idera Pharmaceuticals, Inc. Johnson & Johnson Kadmon Corporation, LLC Kang Stem Biotech Co., Ltd. KPI Therapeutics, Inc. LEO Pharma A/S Lipidor AB Lupin Limited Lycera Corp. Maruho Co., Ltd. MetrioPharm AG Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals, Inc. Mycenax Biotech Inc. NeuClone Pty Ltd Novartis AG Oncobiologics, Inc. Pfizer Inc. Promius Pharma, LLC Protalix BioTherapeutics, Inc. Provectus Biopharmaceuticals, Inc. Sandoz International GmbH Shanghai Celgen Bio-Pharmaceutical Co., Ltd. Sucampo Pharmaceuticals, Inc. Sun Pharma Advanced Research Company Ltd. Takeda Pharmaceutical Company Limited TheraMAB LLC Therapeutic Proteins International, LLC UCB S.A. Valeant Pharmaceuticals International, Inc. XBiotech Inc Ziarco Pharma Ltd

 

Reasons to buy this report


- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Plaque Psoriasis (Psoriasis Vulgaris) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 

Similar Reports

Other reports that may be of interest...

Report... 05IB-GMDHC8865IDBRheumatoid Arthritis - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8834IDBGranulomatosis with Polyangiitis (Wegener Polyangiitis) - Pipeli...Dec 2016
Report... 05IB-GMDHC8821IDBSicca Syndrome (Sjogren) - Pipeline Review, H2 2016Dec 2016
Report... 05IB-GMDHC8820IDBHereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Defi...Dec 2016
Report... 05IB-GMDHC8720IDBAnaphylaxis - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8637IDBSystemic Lupus Erythematosus - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8641IDBLung Transplant Rejection - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8650IDBPemphigus Vulgaris - Pipeline Review, H2 2016Nov 2016
Report... 05IB-GMDHC8594IDBPeanut Allergy - Pipeline Review, H2 2016Oct 2016
Report... 05IB-GMDHC8582IDBHematopoietic Stem Cell Transplantation - Pipeline Review, H2 20...Oct 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

Report 05IB-GMDHC8559IDB has a rating of 93 percent
Figure of merit assessment for report 05IB-GMDHC8559IDB

Relevance Rating

The Research and Experts relevance ranting consists of a set of figure of merit (FOM) values that are provided as an indication of the value of the report in the current economic environment.

These FOM values cannot take into account the reason for the clients interest in a report and therefore the client should view these FOM values only as a visual guide. The FOM scores are based on

market interest - how often the report is viewed or purchased,
elapsed time - time since the report was published,
report detail - amount of detail in the report (pages, figures, images, comments etc.) and
price - the price of the report.


Regional Information

Taxonomy

Branch ID: 1591

Taxonomy Location

The taxonomy on the left shows the ancestors of the Global node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Global

The global economy is the economy of all the world's countries. The total world population now stands at over 7 billion and the global unemployment rate is 9% with approximately half the world's population paid less than $2 a day. 

The global economy is picking up again after five years of uncertaintity and slow economic growth. The IMF is predicting global growth of 3.7% in 2014 rising to 3.9% in 2015. However, much uncertainity remains. Low inflation in developed economies means that these economies take longer to deal with debt burdens and are at increases risk of deflation. 

The second half of 2013 saw growth in the US and European economies (particularly UK, Germany and France).  

Growth in the US has been helped by cheaper energy from fracking , renewables and more oil and gas exploration. This cheaper energy is bring manufacturing jobs back to the US and helping to boost domestic demand. Recent winter weather conditions have hampered growth in the construction sector and have slowed demand in the construction equipment sector which saw exports drop by 25% in 2013. Growth should pick up in this sector with continued federal investment in infrastructure, new residential house builds and refurbishment and the energy boom.

In Europe growth is expected to be uneven with growth being slow in stressed economies such as Portugal and Greece but confidence picking up in UK, Ireland and even Spain showing some improvement.

Developing economies such as China and India will continue to have strong growth in 2014 and 2015. China has benefitted from increased investment with the Chinese govenment now focused on quality growth of 7.5% in 2014. India which is less reliant on exports expects growth of 5.4% in 2014 and 6.4% in 2015.

Much uncertainity still remains in the global economy with greater optimism needed to stabilise growth.

Links

World Bank

IMF (International Monetary Fund)

 

 

Zones

Regional zones

 

Country

Countries

 

Industry Sector Information

Taxonomy

Branch ID: 7198

Taxonomy Location

The taxonomy on the left shows the ancestors of the Immunology node. This provides an insight into parent categories that may provide reports or articles that may compliment this report. The number in brackets after the node name indicates the number of reports that Research and Experts currently have in the parent category.

Clicking on a parent category will present the list of reports in the parent node in a separate window.

Immunology

Immunology

 

Healthcare

The healthcare industry is changing rapidly due to changes in legislation (US Affordable Healthcare Act),  advances in IT and more pressures on governments and healthcare providers due to rising costs. 

According to a recent report by the OECD healthcare spending has fallen in one third of OECD member states due to the credit crunch and members are facing up to the challenge of providing greater care with fewer resources. Spending on healthcare has increased in Japan, Israel and Korea while it has dropped dramatically in Greece and Ireland.

Useful Links

World Health Organisation 

American Healthcare Association

The British Healthcare Business Intelligence Association

OECD, Health Policies and Data

Healthcare

Life Sciences

The Life Sciences industry includes biotechnology, healthcare, pharmaceuticals, medical devices and diagnostics. The industry is dominated by US companies requiring considerable investment in research and development to stay competitive.  While US companies dominate this space, competition is emerging from smaller companies in Europe and Asia. 

Companies trying to stay competitive or enter new markets in life sciences consult our reports. For example, Plimsoll, in their recent review of global antibiotic manufacturers have reviewed 150 of the largest manufacturers including analysis of  ANTIBIOTICE SA, BAYER HEALTHCARE MANUFACTURING SRL and CIPLA LTD. 

Our reports are a requirement for companies looking for the best competitive intelligence in the life sciences sector providing information on market size, rankings, best trading partners and financial analysis. 

Useful Links

Analytical Life Sciences and Diagnostics Association

German Life Sciences Association

 

Life Sciences

Industry

Industries

 

 

Buy: Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016

 

Item Code: 05IB-GMDHC8559IDB

 
Licence: Single User
Price: $2000.00
 
VAT: 0.0% 
Total: $2000.00 

Feedback

Return to Research and Experts

Page created and rendered - Cache updated [1.42910s]

--